How can AI improve donor selection in cell and gene therapy? Machine learning tools are now predicting donor availability, guiding allogeneic selection, and optimizing cell characterization—with measurable results.
In this 60-minute ISCT webinar, Harnessing AI and Advanced Analytics for Donor Selection and Starting Materials, Dr. Robert Tressler, Chief Scientific Officer at Excellos, joins CGT industry leaders to explore the real-world impact of AI/ML on starting-material strategy.
What You’ll Learn
- How AI/ML models predict donor availability and reduce sourcing bottlenecks
- Data-driven approaches to allogeneic donor selection
- Strategies for optimizing cell collection and characterization workflows
- Emerging data and case studies you can apply to your own programs
Why It Matters
Donor selection and starting-material quality directly impact manufacturing success and patient outcomes. AI tools are helping teams move faster, reduce risk, and make more informed decisions earlier in development.
Watch the Webinar
Ready to see how data-driven donor strategy can strengthen your pipeline? Access the full session here.
Partner With Excellos
Looking to optimize your cell and gene therapy manufacturing? Excellos brings deep expertise in starting-material characterization, process development, and scalable CGT production. Contact our team to discuss how we can support your program.
